close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

91.59 +0.24 (+0.26%)
Streaming Delayed Price Updated: 9:48 AM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
News headline image
BioNTech Q2 Earnings Call Highlights ↗
BioNTech (NASDAQ:BNTX) reported second-quarter 2026 revenue of €106 million, down from €261 million a year earlier, as lower U.S. demand for its COVID-19 vaccine weighed on results. The prior-year... 
Via MarketBeat
Topics Earnings
BioNTech (NASDAQ:BNTX) Falls After Q2 Revenue Miss and Revised Full-Year Guidance ↗
Via Chartmill
News headline image
BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring ↗
Could it become as successful in this niche as it was in the coronavirus vaccine market? 
Via The Motley Fool
News headline image
Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock ↗
Cathie Wood's biotech ETF has largely moved on from the vaccine maker. 
Via The Motley Fool
Topics ETFs
BioNTech Q1 2026 Revenue Miss Overshadows Pipeline Progress as NASDAQ:BNTX Slides ↗
Via Chartmill
BioNTech SE (NASDAQ:BNTX) Stock Plummets 17% on Q4 Loss and Co-Founders' Planned Exit ↗
Via Chartmill
BNTX Shares Rise On Goldman Sachs Upgrade, Optimism For Cancer Portfolio ↗
Via Stocktwits
News headline image
2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now ↗
They may not remain cheap for too much longer. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Biotech Stocks Worth Buying Before Their Potential Buyouts ↗
It has been a banner year for biotech buyouts, and these are two of the prime targets. 
Via The Motley Fool
News headline image
BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM ↗
BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a... 
Via MarketBeat
News headline image
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
Investors can find much better opportunities. 
Via The Motley Fool
News headline image
Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors. ↗
This may be an excellent deal for those focused on the long game. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Healthcare Stocks to Buy and 1 to Approach With Caution ↗
Recent performances don't tell the whole story. 
Via The Motley Fool
News headline image
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the... 
Via Finterra
Topics Initial Public Offering
News headline image
The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery
The biotech sector has found its new North Star in 2026. As of mid-March, Moderna Inc. (NASDAQ: MRNA) has shocked Wall Street with a staggering 83% year-to-date gain, catapulting it to the upper... 
Via MarketMinute
Topics Artificial Intelligence Initial Public Offering Stocks
News headline image
Why BioNTech Stock Is Getting Crushed Today ↗
Nothing about the recent past, present, or foreseeable future seems all that compelling. 
Via The Motley Fool
Gapping stocks in Tuesday's session ↗
Via Chartmill
News headline image
BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier
In a watershed moment for the biotechnology sector, BioNTech SE (NASDAQ: BNTX) has reported its full-year 2025 financial results, signaling the definitive end of the COVID-19 vaccine gold rush and the... 
Via MarketMinute
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Why Did BNTX Stock Tumble 17% Pre-Market Today? ↗
BioNTech co-founders Ugur Sahin and Özlem Türeci are set to leave the company to head the new venture. 
Via Stocktwits
News headline image
The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology
On March 6, 2026, Moderna, Inc. (NASDAQ: MRNA) remains the centerpiece of biotech conversations following a staggering 14% surge in its share price earlier this week. For a company that became a... 
Via Finterra
Topics Initial Public Offering Intellectual Property
News headline image
Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement
In a landmark resolution that removes a multi-year shadow over the messenger RNA (mRNA) industry, Moderna, Inc. (NASDAQ:MRNA) has reached a comprehensive $2.25 billion global settlement with Genevant... 
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era
Today’s Date: March 5, 2026 Introduction The narrative surrounding Moderna, Inc. (NASDAQ: MRNA) shifted dramatically this morning as the biotechnology pioneer’s shares surged 15.99%, reclaiming a level... 
Via Finterra
Topics Intellectual Property
News headline image
The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot
As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Moderna (MRNA) Deep Dive: Navigating Regulatory Blows and the Pivot to Oncology
Today, February 11, 2026, marks a volatile chapter for Moderna, Inc. (NASDAQ: MRNA). The biotechnology pioneer, which became a household name during the COVID-19 pandemic, finds itself at a critical... 
Via Finterra
Topics Artificial Intelligence Initial Public Offering Intellectual Property
News headline image
2 Biotech Stocks Set to Rebound in 2026 ↗
They could perhaps see sustained runs beyond this year. 
Via The Motley Fool
News headline image
Moderna and Merck Solidify Oncology Leadership as Five-Year Melanoma Data Fuels Market Rally
In a landmark moment for the future of personalized medicine, Moderna, Inc. (NASDAQ: MRNA) and Merck & Co., Inc. (NYSE: MRK) announced groundbreaking five-year follow-up data on January 20, 2026, for... 
Via MarketMinute
Topics Intellectual Property
News headline image
Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse
As of January 22, 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the poster child for the global pandemic response, the Cambridge-based... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot
Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period... 
Via Finterra
Topics Initial Public Offering Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.